Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Blood (2023) 142 (Supplement 1): 826.

https://doi.org/10.1182/blood-2023-174973

Published: 2023

Journal Articles

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Blood (2023) 142 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2023-189777

Published: 2023

Journal Articles

Different Epidemiology and Characteristics of Invasive Pulmonary Aspergillosis in Acute Lymphoid Leukemia in Comparison with AML: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda (REL)

Chiara Cattaneo, Massimo Bernardi, Nicola Fracchiolla, Federica Gigli, Claudia Basilico, Lorenzo Masina, Erika Borlenghi, Alessandro Bruno, Giselda Gela, Diego Bertoli, Giuseppe Rossi, Alessandra Tucci, Federico Lussana, Elisabetta Todisco

Blood (2023) 142 (Supplement 1): 5827.

https://doi.org/10.1182/blood-2023-181212

Published: 2023

Journal Articles

Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Blood (2023) 142 (Supplement 1): 5997.

https://doi.org/10.1182/blood-2023-185555

Published: 2023

Journal Articles

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Blood (2023) 142 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2023-178505

Published: 2023

Journal Articles

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Blood (2023) 142 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2023-185045

Published: 2023

Journal Articles

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2023) 142 (Supplement 1): 956.

https://doi.org/10.1182/blood-2023-180568

Published: 2023

Journal Articles

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Blood (2023) 142 (Supplement 1): 731.

https://doi.org/10.1182/blood-2023-189025

Published: 2023

Journal Articles

Comparison between Dasatinib-Blinatumomab Vs Ponatinib-Blinatumomab Chemo-Free Strategy for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients. Preliminary Results of the Gimema ALLL2820 Trial

Blood (2023) 142 (Supplement 1): 4249.

https://doi.org/10.1182/blood-2023-189632

Published: 2023

Journal Articles

Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Blood (2022) 140 (Supplement 1): 9054–9056.

https://doi.org/10.1182/blood-2022-160024

Published: 2022

Journal Articles

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1705–1707.

https://doi.org/10.1182/blood-2022-157393

Published: 2022

Journal Articles

Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome

Deborah Cardinali, Irene Della Starza, Vittorio Bellomarino, Marco Beldinanzi, Mariangela Di Trani, Felicetto Ferrara, Monica Bocchia, Prassede Salutari, Monia Lunghi, Erika Borlenghi, Matteo Piccini, Catello Califano, Alfonso Piciocchi, Maria Stefania De Propris, Robin Foà, Sabina Chiaretti

Blood (2022) 140 (Supplement 1): 6350–6351.

https://doi.org/10.1182/blood-2022-163559

Published: 2022

Journal Articles

Prospective and Retrospective Observational Study in Adult and Pediatric Patients with GATA2 Variants (GATA2 Deficiency)

Blood (2022) 140 (Supplement 1): 2957–2959.

https://doi.org/10.1182/blood-2022-168771

Published: 2022

Journal Articles

Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

Pilar Martínez Sánchez, Gerhard Zugmaier, Paul Gordon, Elias Jabbour, José J. Rifón Roca, Stefan Schwartz, Erika Borlenghi, Francoise Huguet, Jesús María Hernández-Rivas, Federico Lussana, Céline Berthon, Priti Kadu, Hansen Wong, Ana Markovic, Yuliya Katlinskaya, Alessandro Rambaldi

Blood (2022) 140 (Supplement 1): 6122–6124.

https://doi.org/10.1182/blood-2022-157117

Published: 2022

Journal Articles

INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 4391.

https://doi.org/10.1182/blood-2021-149157

Published: 2021

Journal Articles

Adverse Prognostic Role of IDH2 Mutations at Diagnosis and during Follow-up in Patients with Acute Myeloid Leukemia and Normal Karyotype

Erika Borlenghi, Diego Bertoli, Chiara Cattaneo, Margherita Sciumé, Elisa Cerqui, Chiara Pagani, Nicola Bianchetti, Margherita Oberti, Rossella Leopaldo, Cecilia Carbone, Silvana Archetti, Giuseppe Rossi, Alessandra Tucci

Blood (2021) 138 (Supplement 1): 2366.

https://doi.org/10.1182/blood-2021-149719

Published: 2021

Journal Articles

Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137092

Published: 2020

Journal Articles

Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)

Chiara Cattaneo, MD, Massimo Bernardi, MD, Valentina Mancini, MD, Chiara Pagani, MD, Monica Fumagalli, MD, Patrizia Zappasodi, MD, Erika Borlenghi, MD, Alessandro Re, MD, Fabio Ciceri, MD, Margherita Sciumé, Roberto Cairoli, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 3603.

https://doi.org/10.1182/blood-2019-125288

Published: 2019

Journal Articles

Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06

Blood (2019) 134 (Supplement_1): 1443.

https://doi.org/10.1182/blood-2019-124497

Published: 2019

Journal Articles

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

Erika Borlenghi, MD, Chiara Pagani, MD, Michele Malagola, MD, Diego Bertoli, PhD, Francesca Schieppati, MD, Silvana Archetti, PhD, Angela Passi, MD, Cinzia Lamorgese, Chiara Cattaneo, MD, Nicola Polverelli, Margherita Sciumé, Rosa Daffini, MD, Doriana Gramegna, MD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 2695.

https://doi.org/10.1182/blood-2019-126074

Published: 2019

NARROW

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Different Epidemiology and Characteristics of Invasive Pulmonary Aspergillosis in Acute Lymphoid Leukemia in Comparison with AML: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda (REL)

Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Comparison between Dasatinib-Blinatumomab Vs Ponatinib-Blinatumomab Chemo-Free Strategy for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients. Preliminary Results of the Gimema ALLL2820 Trial

Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome

Prospective and Retrospective Observational Study in Adult and Pediatric Patients with GATA2 Variants (GATA2 Deficiency)

Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Adverse Prognostic Role of IDH2 Mutations at Diagnosis and during Follow-up in Patients with Acute Myeloid Leukemia and Normal Karyotype

Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results

Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)

Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only